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HLA-Cw6 and the Genetic Predisposition to Psoriasis: a
Meta-Analysis of Published Serologic Studies
To the Editor:
Postulated genetic factors in psoriasis include human leukocyte
antigen associations. HLA-Cw6 is the most frequently described
association and has been confirmed in many racial groups. The
frequency of many HLA-C alleles, however, is underestimated by
serology and some antigens such as HLA-Cw6 are thought to be
consistently assigned incorrectly by serology (Bunce et al, 1996).
The low surface expression of HLA-C molecules together with
the lack of typing reagents account for the fact that 20%–50% of
populations studied so far carry undefined HLA-C alleles, collect-
ively called Cw ‘‘blank’’ (Levine and Yang, 1994). Using a high
resolution polymerase chain reaction with sequence-specific primers
we have recently reported the strong association of HLA-Cw*0602
in a U.K. Caucasian population with chronic plaque psoriasis
(Mallon et al, 1997), HIV-associated psoriasis (Mallon et al, 1998),
and streptococcal associated guttate psoriasis.1
Case-control HLA association studies are limited by the fact that
control populations may be derived from a different gene pool.
Recent evidence from genetic linkage studies supports a role for
the HLA-C locus in the pathogenesis of chronic plaque psoriasis;
linkage to the major histocompatibility complex region on chromo-
some 6p21 (including to the HLA-C locus) has been demonstrated
indicating that one or more genes located within the major
histocompatibility complex and close to class I HLA loci may
represent the major determinant of the genetic basis of psoriasis
(Trembath et al, 1997). We thought it worthwhile to examine all
available published data on the association of HLA-Cw6 with
psoriasis. We have examined data from serologic studies investigating
HLA-C antigens in psoriasis and included all studies that provided
usable data up to December 1998. The results emphasize the
importance of HLA-C, or a gene in linkage disequilibrium with
HLA-C, in the predisposition to psoriasis, particularly in guttate
psoriasis and psoriasis of early onset.
Medline, PubMed, and EMBASE database searches were per-
formed to obtain all published serologic studies available from 1966
to December 1998: MeSH (medical subjects heading) terms used
were ‘‘immunogenetics and psoriasis’’; ‘‘HLA and psoriasis’’; and
‘‘HLA-C and psoriasis’’. References were also sought from published
research by using the Science Citation Index and by searching
references in published studies and abstracts. The search was not
restricted to the English language. Inclusion criteria for studies
incorporated in the meta-analysis were that: (i) HLA-Cw6 was
included in the investigation of HLA associations in patients with
psoriasis; (ii) a control population without psoriasis was also studied;
and (iii) a study did not use the same data as previous studies. The
search uncovered 14 studies (Brenner et al, 1978; Murray et al,
1980; Tiilikainen et al, 1980; Laurentaci et al, 1982; Armstrong
et al, 1983; Economidou et al, 1985; Ozawa et al, 1988; Nakagawa
et al, 1991; Chablani et al, 1992; Cao et al, 1993; Ika¨heimo et al,
1994; Roitberg-Tambur et al, 1994; Gonzaga et al, 1996; Schmitt-
Egenolf et al, 1996) that met these inclusion criteria. Relevant
data (HLA-C phenotype frequencies in cases and controls) were
extracted from the published papers obtained (Table I). Odds
ratios, confidence limits, and significance values for HLA-Cw6
were calculated (Table II) using Epi Info Version 6 (1996). Meta-
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analysis was performed on the results of HLA-Cw6 typing by
logistic regression using the Stata Statistical Package (Stata Statistical
Software, 1997). Baseline odds for psoriasis in Cw6 negative patients
was estimated for each individual study and a common odds ratio,
interpreted as the relative risk, was estimated over all studies.
Robust variance formulae were used to calculate confidence limits,
allowing for the possibility that true relative risks might vary slightly
from one study to another, so that the common relative risk would
be an appropriately weighted average. Meta-analysis was performed
on studies in each of five psoriasis subgroups: group 1, early-onset
psoriasis; group 2, late-onset psoriasis; group 3, guttate psoriasis
(one study only); group 4, psoriasis of unspecified type; group 5,
psoriasis vulgaris. Three studies (Brenner et al, 1978; Tiilikainen
et al, 1980; Schmitt-Egenolf et al, 1996) were included in the meta-
analysis of more than one group.
Meta-analysis (Table III) showed that HLA-Cw6 predicted
guttate psoriasis more strongly than type I psoriasis, and type I
psoriasis more strongly than type II psoriasis. The other two types
of psoriasis (vulgaris and unspecified) are probably mixtures of these
three types and show intermediate odds ratios.
This meta-analysis is of limited value because publication bias
makes it more likely that significant positive associations are
published compared with non-significant associations (Easterbrook
et al, 1991) and an accurate meta-analysis should include unpublished
data (Bland, 1995). In order to include unpublished data in the
meta-analysis of HLA-Cw6 serologic typing results in psoriasis, we
invite the contribution of unpublished HLA-C serologic typing
results to the authors of this letter.
Eleanor Mallon, Roger Newson,* Christopher B. Bunker
Departments of Dermatology and *Public Health, Chelsea &
Westminster Hospital, Imperial College School of Medicine,
London, U.K.
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Table I. HLA-Cw6 typing results in serologic studies used in meta-analysis
Psoriasis Study Cases Controls Cases Controls
type (country) Cw6 1ve Cw6 1ve Cw6 –ve Cw6 –ve
Ia Brenner et al, 1978 (Austria) 48 32 9 93
Ib Schmitt-Egenolf et al, 1996 (Germany) 49 31 11 115
IIc Brenner et al, 1978 (Austria) 9 32 11 93
IId Schmitt-Egenolf et al, 1996 (Germany) 13 31 17 115
Guttate Tiilikainen et al, 1980 (Finland) 16 34 6 428
Unspecified Brenner et al, 1978 (Austria) 57 32 20 93
Unspecified Murray et al, 1980 (USA) 30 17 30 109
Unspecified Armstrong et al, 1983 (England) 42 32 12 121
Unspecified Economidou et al, 1985 (Greece) 33 30 58 172
Unspecified Ozawa et al, 1988 (Japan) 27 13 77 937
Psoriasis vulgaris Tiilikainen et al, 1980 (Finland) 17 34 20 428
Psoriasis vulgaris Laurentaci et al, 1982 (Italy) 54 24 68 152
Psoriasis vulgaris Nakagawa et al, 1991 (Japan) 7 0 72 100
Psoriasis vulgaris Chablani et al, 1992 (India) 36 37 31 95
Psoriasis vulgaris Cao et al, 1993 (China) 2 1 10 99
Psoriasis vulgaris Ika¨heimo et al, 1994 (Finland) 35 10 30 178
Psoriasis vulgaris Roitberg-Tambur et al, 1994 (Israel) 7 46 21 212
Psoriasis vulgaris Gonzaga et al, 1996 (Brazil) 13 20 9 139
Psoriasis vulgaris Schmitt-Egenolf et al 1996 (Germany) 62 31 28 115
aAge of onset between 10 and 20 y.
bAge of onset , 30 y.
cAge of onset between 35 and 45 y.
dAge of onset . 40 y.
Table II. Odds ratio for HLA-Cw6 and psoriasis from serologic studies
Psoriasis type Study n Odds ratio 95% CLa p-valueb
Ic Brenner et al, 1978 57 15.50 6.50, 39.39 0.000000
Id Schmitt-Egenolf et al, 1996 60 16.62 7.30, 38.94 0.000000
IIe Brenner et al, 1978 20 2.38 0.79, 6.94 0.106200
IIf Schmitt-Egenolf et al, 1996 30 2.84 1.13, 6.95 0.018900
Guttate Tiilikainen et al, 1980 22 33.57 11.37, 109.83 0.000000
Unspecified Brenner et al, 1978 77 8.28 4.14, 16.75 0.000000
Unspecified Murray et al, 1980 60 6.41 2.95, 14.07 0.000000
Unspecified Armstrong et al, 1983 54 13.23 5.93, 30.54 0.000000
Unspecified Economidou et al, 1985 91 3.26 1.75, 6.05 0.000094
Unspecified Ozawa et al, 1988 104 25.27 11.95, 55.25 0.000000
Psoriasis vulgaris Tiilikainen et al, 1980 37 10.70 4.75, 23.63 0.000000
Psoriasis vulgaris Laurentaci et al, 1982 122 5.03 2.78, 9.20 0.000000
Psoriasis vulgaris Nakagawa et al, 1991 79 ` 1.92, ` 0.002794
Psoriasis vulgaris Chablani et al, 1992 67 2.98 1.54, 5.75 0.000570
Psoriasis vulgaris Cao et al, 1993 12 19.80 0.90, 1178.95 0.029923
Psoriasis vulgaris Ika¨heimo et al, 1994 65 20.77 8.89, 51.31 0.000000
Psoriasis vulgaris Roitberg-Tambur et al, 1994 28 1.54 0.52, 4.03 0.440371
Psoriasis vulgaris Gonzaga et al, 1996 22 10.04 3.40, 29.88 0.000004
Psoriasis vulgaris Schmitt-Egenolf et al, 1996 90 8.21 4.34, 15.61 0.000000
aConfidence limits.
bFisher’s exact (two-tailed) p value is given.
cPsoriasis vulgaris ‘‘including eruptive type, plaque type and seborrhoeic type’’; age of onset between 10 and 20 y.
d‘‘Chronic stable psoriasis’’; age of onset , 30 y.
ePsoriasis vulgaris ‘‘including eruptive type, plaque type and seborrhoeic type’’; age of onset between 35 and 45 y.
f‘‘Chronic stable psoriasis’’; Age of onset . 40 y.
Table III. Meta-analysis of serologic studies
Psoriasis type No of studies Odds ratio p value 95% confidence interval
Type I 2 16.04 0.000 9.17, 28.07
Type II 2 2.63 0.003 1.40, 4.94
Guttate 1 33.57 0.000 12.32, 91.45
Unspecified 5 8.48 0.000 6.21, 11.57
Psoriasis vulgaris 9 6.46 0.000 4.99, 8.36
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